Cogent BiosciencesCOGT
COGT
About: Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Employees: 205
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
60% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 20
32% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 50
7.05% more ownership
Funds ownership: 110.19% [Q4 2024] → 117.24% (+7.05%) [Q1 2025]
5% more funds holding
Funds holding: 175 [Q4 2024] → 184 (+9) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 8 [Q4 2024] → 8 (+0) [Q1 2025]
16% less capital invested
Capital invested by funds: $949M [Q4 2024] → $800M (-$150M) [Q1 2025]
75% less call options, than puts
Call options by funds: $355K | Put options by funds: $1.42M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
22%
downside
Avg. target
$21
80%
upside
High target
$29
152%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
Citigroup David Lebowitz | 91%upside $22 | Buy Maintained | 18 Jul 2025 |
JP Morgan Anupam Rama | 152%upside $29 | Overweight Maintained | 10 Jul 2025 |
HC Wainwright & Co. Robert Burns | 91%upside $22 | Buy Maintained | 8 Jul 2025 |
Guggenheim Michael Schmidt | 47%upside $17 | Buy Reiterated | 8 Jul 2025 |
Baird Joel Beatty | 22%downside $9 | Neutral Maintained | 8 Jul 2025 |
Financial journalist opinion
Based on 8 articles about COGT published over the past 30 days
Positive
24/7 Wall Street
1 week ago
2 Biotech and 2 Tech Stocks Insiders Are Scooping Up Now
Insider buying has been slow this month, as buy windows close ahead of the new earnings-reporting season.
Neutral
GlobeNewsWire
2 weeks ago
Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass. and BOULDER, Colo., July 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its previously announced upsized underwritten public offering of 25,555,556 shares of its common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The public offering price was $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were sold by Cogent.
Positive
Seeking Alpha
3 weeks ago
Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results
I have upgraded Cogent Biosciences, Inc. to Strong Buy after positive SUMMIT trial data for bezuclastinib in non-advanced systemic mastocytosis patients. COGT plans to submit an NDA for bezuclastinib in NonAdvSM by end of 2025, with additional pivotal data readouts expected in AdvSM and GIST in 2nd half 2025. Cogent is well-funded, raising $200M recently and maintaining a cash runway into late 2026, supporting ongoing and upcoming clinical milestones.
Neutral
GlobeNewsWire
3 weeks ago
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
3 weeks ago
Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $150 million of its shares of common stock. In addition, Cogent intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its shares of common stock on the same terms and conditions. All of the securities in the offering are being offered by Cogent. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Positive
Zacks Investment Research
3 weeks ago
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success
Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.
Positive
Benzinga
3 weeks ago
Why Is Cogent Biosciences Stock Trading Higher On Monday?
Cogent Biosciences, Inc.‘s COGT bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis, a rare and debilitating immune disorder.
Neutral
GlobeNewsWire
3 weeks ago
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis
-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo --
Neutral
GlobeNewsWire
1 month ago
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
Facility provides additional funding for next steps of the Company's growth, including the expected launch of bezuclastinib in 2026 On track to report results from three pivotal trials this year, beginning with SUMMIT results in July WALTHAM, Mass. and BOULDER, Colo.
Neutral
GlobeNewsWire
2 months ago
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo.
Charts implemented using Lightweight Charts™